Health Canada
Symbol of the Government of Canada

Common menu bar links

Help the Government of Canada organize its website! Complete an anonymous 5-minute questionnaire. Start now.
Drugs and Health Products

Canadian Adverse Reaction Newsletter, Volume 21 - Issue 2 - April 2011

ISSN 1499-9447
Cat no H42-4/1-21-2E

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

Health Products and Food Branch
Marketed Health Products Directorate
Canadian Adverse Reaction Newsletter Editorial Team

In this Issue:

Scope

This quarterly publication alerts health professionals to potential signals detected through the review of case reports submitted to Health Canada. It is a useful mechanism to stimulate adverse reaction reporting as well as to disseminate information on suspected adverse reactions to health products occurring in humans before comprehensive risk-benefit evaluations and regulatory decisions are undertaken. The continuous evaluation of health product safety profiles depends on the quality of your reports.

CARN turns 20

Since 1991, the Canadian Adverse Reaction Newsletter (CARN) has strived to provide feedback on adverse reaction (AR) reports received by Health Canada and to stimulate AR reporting. CARN continues to be an early-stage risk communication tool, summarizing information on suspected ARs to raise awareness of emerging safety issues with health products.

We thank our many readers and all those who have contributed to the Newsletter over the years.

Did you know?

Starting in 2011, annual statistics on adverse reaction and incident reporting will now appear in the July issue of the Newsletter.

Reporting Adverse Reactions
Canada Vigilance Program
Phone: 1-866-234-2345
Fax: 1-866-678-6789

For more information on how to report an adverse reaction, visit the Reporting Adverse Reactions to Drugs and Other Health Products page.

Caveat: Adverse reactions (ARs) to health products are considered to be suspicions, as a definite causal association often cannot be determined. Spontaneous reports of ARs cannot be used to estimate the incidence of ARs because ARs remain underreported and patient exposure is unknown.

Some of the hyperlinks provided are to sites of organizations or other entities that are not subject to the Next link will take you to another Web site Official Languages Act. The material found there is therefore in the language(s) used by the sites in question.

Fluticasone propionate and osteonecrosis

Key points

  • Health Canada received 5 reports of osteonecrosis suspected of being associated with fluticasone propionate.
  • The potential for osteonecrosis with high doses of inhaled corticosteroids has been suggested in the literature.
  • Because corticosteroid-induced osteonecrosis tends to occur in younger patients and treatment options for advanced disease are limited, early identification is important.

Fluticasone propionate is a highly potent glucocorticoid anti-inflammatory steroid. In Canada, it is available as an aqueous nasal spray, an inhalation aerosol, a powder for inhalation and a topical cream (Table 1).1, 2, 3

Steroid-induced osteonecrosis, or avascular necrosis, is characterized by bone cell death resulting from compromised blood supply. Corticosteroids, administered orally or parenterally, have been associated with osteonecrosis.4 Osteonecrosis related to inhaled or topical use of steroids has also been reported, but the oral or parenteral use of steroids was a confounding factor.4 The potential for osteonecrosis with high doses of inhaled corticosteroids, such as in the treatment of severe persistent asthma or eosinophilic esophagitis, has been suggested.4

As of Oct. 31, 2010, Health Canada received 5 reports of osteonecrosis suspected of being associated with fluticasone propionate. In one report, a 33-year-old man had avascular necrosis of both hips requiring surgery after using inhaled fluticasone 3 times a day for several years. A history of previous steroid therapy (type not specified) was the only identified risk factor reported. Another report of osteonecrosis involved a 46-year-old man who had been using Advair Diskus for 4 months, Flovent and another inhaled corticosteroid (beclomethasone) for about 8 years, and Flonase Nasal Spray occasionally for about 3 years. The report did not state any previous use of systemic corticosteroids. The other 3 reports contained limited information.

Systemic adverse reactions may occur with intranasal and inhaled use of corticosteroids.1,2 The long-term effects of fluticasone propionate are still unknown. The relative determinants of systemic adverse reactions to inhaled and intranasal corticosteroids have been assessed, and fluticasone propionate was determined to have a high systemic potency.5 Because corticosteroid-induced osteonecrosis tends to occur in younger patients (the average age at onset is 33) and treatment options for advanced disease are limited, early identification is important.4 Health care professionals, patients and caregivers should be aware of the potential for osteonecrosis with inhaled or intranasal corticosteroids and are encouraged to report any suspected cases to Health Canada.

Table1: Products containing fluticasone propionate available on the Canadian market.
Product (year of marketing) Route of administration Indication

Generic products are also available for intranasal spray.

Fluticasone propionate/salmeterol xinafoate combination products.

Flonase (1993) Intranasal Allergic rhinitis2
Flovent Diskus (1998) Inhalation Prophylactic management of asthma in children and adults1
Flovent HFA (2001) Inhalation Prophylactic management of asthma in children and adults1
Advair Diskus (1999) and Advair HFA (2001) Inhalation Maintenance treatment of asthma and chronic obstructive pulmonary disease in patients when the use of a combination product is considered appropriate3
Cutivate (2004) Topical cream Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

Nadiya Jirova, MSc, Health Canada

References

  1. Flovent HFA, Flovent Diskus (fluticasone propionate) [product monograph]. Mississauga (ON): GlaxoSmithKline Inc.; 2010.
  2. Flonase (fluticasone propionate) [product monograph]. Mississauga (ON): GlaxoSmithKline Inc.; 2004.
  3. Advair Diskus (salmeterol xinafoate/fluticasone propionate) [product monograph]. Mississauga (ON): GlaxoSmithKline Inc.; 2008.
  4. Powell C, Chang C, Naguwa S, et al. Next link will take you to another Web site Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmun Rev 2010;9(11):721-43. [PubMed]
  5. Lipworth BJ, Jackson CM. Next link will take you to another Web site Safety of inhaled and intranasal corticosteroids. Drug Saf 2000;23(1):11-33. [PubMed]

Rosiglitazone-fenofibrate interaction: severe paradoxical decreased high-density lipoprotein cholesterol levels

Key points

  • Health Canada received 8 reports of decreased high-density lipoprotein (HDL) cholesterol levels in patients using rosiglitazone and fenofibrate concomitantly.
  • Observational studies and case reports support the possible occurrence of severe paradoxical lowering of HDL cholesterol with the use of various fibrates (e.g., fenofibrate, bezafibrate).
  • Some studies and case reports suggest that, in some patients, such decreases involve the interaction of rosiglitazone with fenofibrate or bezafibrate.

Rosiglitazone is indicated in Canada to improve glycemic control in patients with type 2 diabetes mellitus when all other oral antidiabetic agents are inadequate, contraindicated or cannot be tolerated.1 It was marketed for the first time in Canada in 2000 under the brand name Avandia. Fenofibrate is indicated for the treatment of several forms of dyslipidemia.2 It was marketed for the first time in Canada in 1990 under the brand name Lipidil.

Both drugs are known to increase serum concentrations of high-density lipoprotein (HDL) cholesterol.1, 2 Severe paradoxical decreases of HDL cholesterol (defined as ‹ 0.52 mmol/L) associated with the concomitant use of rosiglitazone and fenofibrate have been reported in the literature.3 Serum concentrations of HDL cholesterol below 1.03 mmol/L are considered to be a risk factor for cardiovascular disease.4, 5

As of Sept. 30, 2010, Health Canada received 8 reports of decreased HDL cholesterol levels in patients using rosiglitazone and fenofibrate concomitantly. In these patients, the lowest reported levels ranged from 0.02 to 0.43 mmol/L. One of the reports was described in the Canadian Adverse Reaction Newsletter in 2005.6 Another was published in the literature.7 In 3 of the 8 patients, the HDL cholesterol levels improved after discontinuation of rosiglitazone while fenofibrate was continued. In another patient, the HDL cholesterol level improved after discontinuation of both drugs. One of these cases was discovered during the clinical investigation for an acute stroke. None of the patients died.

Observational studies and case reports have reported the possible occurrence of a severe decrease in HDL cholesterol levels with the use of various fibrates (fenofibrate, bezafibrate or ciprofibrate) without concurrent exposure to rosiglitazone.3, 8, 9, 10 However, additional study data and recently published case reports suggest that, in some patients, such decreases involve the interaction of rosiglitazone with fenofibrate or bezafibrate.3, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18

Rosiglitazone is a peroxisome proliferator-activated receptor (PPAR)-γ agonist,1 and fenofibrate is a PPAR-α agonist.2 It has been suggested that genetic polymorphisms in the response to PPAR agonists could influence the metabolism of apolipoprotein AI, the major lipoprotein of HDL cholesterol.12, 13, 14 The mechanism of action for the potential interaction between rosiglitazone and fenofibrate remains unknown.

Health professionals are encouraged to report any cases of decreased HDL cholesterol levels suspected of being associated with fenofibrate and rosiglitazone used alone or in combination.

Patrice Tremblay, MD, Health Canada

References

  1. Avandia (rosiglitazone) [product monograph]. Mississauga (ON): GlaxoSmithKline Inc.; 2010.
  2. Lipidil EZ (fenofibrate, nanocrystal formulation) [product monograph]. Markham (ON): Fournier Pharma Inc.; 2007.
  3. Goldberg RB, Mendez AJ. Next link will take you to another Web site Severe acquired (secondary) high-density lipoprotein deficiency. J Clin Lipidol 2007;1(1):41-56. [PubMed]
  4. American Heart Association. Next link will take you to another Web site Cholesterol: About Cholesterol. Dallas (TX): The Association; (accessed 2010 Mar 28).
  5. National Cholesterol Education Program. Next link will take you to another Web site Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III): executive summary. Bethesda (MD): National Institutes of Health; 2001. (accessed 2010 Oct 20).
  6. Willcox D. Rosiglitazone (Avandia): decreased high-density lipoprotein cholesterol levels. Can Advers Reaction Newsl 2005;15(3):2. (accessed 2010 Oct 20).
  7. Gutschi LM, Malcolm JC, Favreau CM, et al. Next link will take you to another Web site Paradoxically decreased HDL-cholesterol levels associated with rosiglitazone therapy. Ann Pharmacother 2006;40(9):1672-6. [PubMed]
  8. Mymin D, Dembinski T, Friesen MH. Next link will take you to another Web site Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol 2009;49(7):865-71. [PubMed]
  9. Magee G, Sharpe PC. Next link will take you to another Web site Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. J Clin Pathol 2009;62(3):250-3. [PubMed]
  10. Glaysher J, van Heyningen C. Paradoxical decrease in high density lipoprotein-cholesterol associated with statin and fenofibrate combination therapy. Br J Diabetes Vasc Dis 2007;7(6):295-7.
  11. Normn L, Frohlich J, Montaner J, et al. Next link will take you to another Web site Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol. Diabetes Care 2004; 27(9):2241-2. [PubMed]
  12. Keidar S, Guttmann H, Stam T, et al. Next link will take you to another Web site High incidence of reduced plasma HDL cholesterol in diabetic patients treated with rosiglitazone and fibrate. Pharmacoepidemiol Drug Saf 2007;16(11):1192-4. [PubMed]
  13. Alvarez CA, Russell NM, Edwards KL, et al. Next link will take you to another Web site Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population. J Clin Lipidol 2008;2(6):447-52. [PubMed]
  14. Schwing W, Hustak L, Taylor HC. Next link will take you to another Web site Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction. Endocr Pract 2010;16(3):382-8. [PubMed]
  15. Saraf S, Nishtala S, Parretti H, et al. Paradoxical fall in HDL cholesterol observed in a patient treated with rosiglitazone and pioglitazone. Br J Diabetes Vasc Dis 2009;9(4):186-9.
  16. Venero CV, Thompson PD, Fernandez AB. Next link will take you to another Web site Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate. Am J Med 2008;121(10):e3-4. [PubMed]
  17. Shetty C, Balasubramani M, Capps N, et al. Next link will take you to another Web site Paradoxical HDL-C reduction during rosiglitazone and fibrate treatment. Diabet Med 2007;24(1):94-7. [PubMed]
  18. Im M, Kim M, Lee JK, et al. Next link will take you to another Web site [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia]. Korean J Lab Med 2010;30(1):17-9. [PubMed]

Varenicline and hyperglycemia in patients with diabetes

Key points

  • Health Canada received 18 reports of hyperglycemia suspected of being associated with varenicline in patients with type 1 and type 2 diabetes.
  • Of these 18 reports, 7 described a positive dechallenge.

Varenicline (Champix) is indicated for smoking-cessation treatment in adults in conjunction with smoking-cessation counselling.1 The current Canadian product monograph lists diabetes mellitus and hypoglycemia under "less common clinical trial adverse drug reactions" and describes these adverse reactions (ARs) as infrequent and rare, respectively.1

From the date of marketing in April 2007 to Sept. 30, 2010, Health Canada received 18 reports of hyperglycemia suspected of being associated with varenicline in patients with type 1 and type 2 diabetes (Table 1). Of these 18 reports, 2 indicated that the patient required hospital admission. Seven of the reports described a positive dechallenge (abatement of AR upon stopping or reducing the dosage of varenicline), and one described a negative dechallenge (the AR did not subside after discontinuation of varenicline). In one patient, blood glucose levels were reported to increase after each dose of varenicline. Diabetes mellitus is a chronic metabolic disorder characterized by the presence of hyperglycemia and consequently is a confounder in all of the cases. Other confounders identified in some of the reports included infection, medications (e.g., insulin, oral antidiabetic agents, diuretics), alcohol consumption and smoking cessation. In some instances, the patient was still smoking while taking varenicline.

No reports of hyperglycemia suspected of being associated with varenicline in patients with diabetes were found in the medical literature. In one published report describing multiple episodes of hypoglycemia in a diabetic patient after starting varenicline, recommendations were made to intensify home-monitoring of plasma glucose levels.2

Voluntary reporting to Health Canada is an important postmarketing surveillance tool to obtain valuable information about ARs to health products. Health care professionals and patients are encouraged to report ARs suspected of being associated with varenicline.

Table 1: Summary of 16 reports of hyperglycemia suspected of being associated with varenicline in patients with diabetes submitted to Health Canada as of Sept. 30, 2010
Case Age/sex Onset of reaction Dechallenge Increase in blood glucose level, mmol/L Concomitant health products

Two of the 18 reports are not included in the table because they contained limited information.

These data cannot be used to determine the incidence of adverse reactions (ARs) because ARs are underreported and neither patient exposure nor the amount of time the drug was on the market has been taken into consideration.

Estimated from the beginning of treatment.

Response to withdrawal of the drug. Abatement of the reaction after the drug is stopped or the dose is reduced is considered a positive dechallenge.

1 63/F 10 days Positive To 12; (to 70 the following day) Insulin lispro and NPH, ramipril, furosemide
2 52/F 4 days Positive From 5.7 to 16 Metformin, enteric-coated ASA, atorvastatin, metoclopramide, nifedipine, pantoprazole, perindopril, triamterene, hydrochlorothiazide
3 NA/M 3 days Positive To 22 Insulin, unspecified hypocholesterolemic agent, levothyroxine sodium
4 50/M Unknown Positive To 30 Rosiglitazone, cilazapril, lansoprazole, oxycodone, topiramate
5 49/F Unknown Positive To 16-19 Glyburide, metformin, ASA, rosuvastatin
6 42/F Unknown Positive To 35 Metformin, cetirizine, pantoprazole, pravastatin, salbutamol, venlafaxine, verapamil
7 43/F 2 days Unclear From 5-13 to 31-33 Insulin NPH and R, pancrelipase, budesonide / formoterol inhaler, clonazepam, rabeprazole, spironolactone
8 NA/NA 2 days Unknown From 7 to 18-20 Multiple antidiabetic medications (detail not provided in report)
9 57/M 3 days Negative To 15 Glyburide, metformin, diltiazem, doxazosin, hydrochlorothiazide, losartan, omeprazole, simvastatin
10 40/F Unknown Not applicable To 20 Insulin
11 NA/F Unknown Unknown From 6-13 to 24-30 Insulin
12 50/F Unknown Unknown From 7 to 17-18 Insulin glargine (reported as co-suspect), insulin lispro, enteric-coated ASA, calcium and vitamin D, mesalazine
13 65/M Unknown Unknown From 5.5 to 19 Insulin, atorvastatin, doxazosin, ezetimibe, pantoprazole, ramipril
14 59/M Unknown Not applicable To 33 Glyburide; report stated patient was taking about 10 concomitant medications for hypertension, cholesterol and gout
15 60/M Unknown Unknown To 16-17 Insulin, naproxen, lorazepam
16 66/F Unknown Positive To above 33 Metformin, glyburide, enteric-coated ASA

Note: ASA = acetylsalicylic acid, NA = not available.

Maria Longo, RPh, BScPharm, Health Canada

References

  1. Champix (varenicline) [product monograph]. Kirkland (QC): Pfizer Canada Inc; 2010.
  2. Kristensen PL, Pedersen-Bjergaard U, Thorsteinsson B. Next link will take you to another Web site Varenicline may trigger severe hypoglycaemia in type 1 diabetes. Diabet Med 2008;25(5):625-6. [PubMed]

Quinine sulfate and serious adverse reactions

Key points

  • Quinine sulfate is not indicated in Canada for the prevention or treatment of nocturnal leg cramps.
  • Health Canada received 71 reports of serious adverse reactions suspected of being associated with the use of quinine sulfate, including 41 that were life-threatening or required hospital admission.
  • Among the reports that specified the indication for use, 43 listed cramps (leg, muscle or nocturnal leg). Twenty of these reports listed thrombocytopenia, often severe, as the adverse reaction.

Quinine sulfate, in combination with a second antimalarial drug, is recommended in Canada for the treatment of uncomplicated Plasmodium falciparum malaria.1 The recommended dose for adults is 600 mg (equivalent to 500 mg of quinine base) orally, 3 times a day for 3-7 days.1 Quinine sulfate has been marketed in Canada since 1951.

Quinine sulfate is not indicated in Canada for the prevention or treatment of nocturnal leg cramps. The Canadian Pharmacists Association monograph available in the Compendium of Pharmaceuticals and Specialties (CPS) was updated in 2010 to emphasize this.2 However, quinine sulfate is used for the prevention and treatment of leg cramps, at a dose of 200 to 300 mg at bedtime.2 The use of quinine sulfate to prevent leg cramps has been a subject of recent concern. Several international regulators have taken actions to either withdraw this indication for use or have added conditions for its use for leg cramps.3, 4, 5, 6 In addition, the US Food and Drug Administration has recently approved a risk management plan to warn against the use of quinine for leg cramps.7

As of Sept. 30, 2010, Health Canada received 71 reports of serious* adverse reactions (ARs) suspected of being associated with the use of quinine sulfate. Forty-one of the reports mentioned ARs that were either life-threatening or required hospital admission. Only 4 of the 71 reports listed malaria as the indication for use of the drug. Of the remaining 67 reports, 43 listed cramps, leg cramps, muscle cramps or nocturnal leg cramps as the indication for use; 17 of them were received after 2000. For the remaining 24 reports, the indication for use could not be determined or other uses were listed (e.g., neuropathic pain).Twenty of the 43 reports listed thrombocytopenia, often severe, as the AR. Other ARs included Stevens-Johnson syndrome, vasculitis and arrhythmia.

ARs to quinine sulfate include life-threatening blood-related reactions, such as sudden, severe thrombocytopenia.8 Reports of potentially fatal hypersensitivity reactions, particularly quinine-induced thrombocytopenia, are of particular concern, because these reactions are not dose-related and their occurrence is unpredictable. Profound thrombocytopenia can occur rapidly within days or occur after months or years of use.9

Health care professionals are reminded of the serious ARs suspected of being associated with the use of quinine sulfate and that quinine sulfate is not indicated for the prevention or treatment of nocturnal leg cramps.

Catherine Younger-Lewis, MD, Health Canada


* In the Food and Drugs Act and Regulations, a serious AR is defined as "a noxious and unintended response to a drug that occurs at any dose and that requires in-patient hospitalization or prolongation of existing hospitalization, causes congenital malformation, results in persistent or significant disability or incapacity, is life-threatening or results in death."

References

  1. CATMAT. Next link will take you to another Web site Canadian recommendations for the prevention and treatment of malaria among international travellers 2009. Can Commun Dis Rep 2009;35(Suppl 1):1-82.
  2. Next link will take you to another Web site Quinine sulfate [Canadian Pharmacists Association monograph]. In: e-CPS. Ottawa (ON): Canadian Pharmacists Association; 2010. (accessed 2011 Jan 13).
  3. Adverse Drug Reactions Advisory Committee (ADRAC). Next link will take you to another Web site Quinine indications - cramps deleted. Aust Adv Drug Reactions Bull 2004;23(5):20. (accessed 2011 Jan 9).
  4. Medsafe. Next link will take you to another Web site Quinine - not for leg cramps anymore. Prescriber Update 2007;28(1):2-3. (accessed 2011 Jan 9).
  5. US Food and Drug Administration. Next link will take you to another Web site Quinine sulfate (marketed as Qualaquin): off-label (not approved by FDA) use of quinine. FDA Drug Safety Newsletter 2009;2(2):11-3. (accessed 2011 Jan 9).
  6. Medicines and Healthcare products Regulatory Agency. Next link will take you to another Web site Quinine: not to be used routinely for nocturnal leg cramps. Drug Safety Update 2010;3(11):3-4. (accessed 2011 Jan 9).
  7. Next link will take you to another Web site FDA Drug Safety Communication: New risk management plan and patient Medication Guide for Qualaquin (quinine sulfate). Rockville (MD): US Food and Drug Administration; 2010 Aug 7. (accessed 2011 Jan 9).
  8. Aster RH, Bougie DW. Next link will take you to another Web site Drug-induced immune thrombocytopenia. N Engl J Med 2007;357(6):580-7. [PubMed]
  9. Brinker AD, Beitz J. Next link will take you to another Web site Spontaneous reports of thrombocytopenia in association with quinine: clinical attributes and timing related to regulatory action. Am J Hematol 2002;70(4):313-7. [PubMed]

Quarterly Summary of health professional and consumer advisories

(posted on Health Canada's Web site: November 13, 2010 - February 18, 2011)

Date Product Subject
Date of issuance. This date may differ from the posting date on Health Canada's Web site.
Feb 17 Lubricating jelly
products
Additional recall of lubricating jelly products
Feb 16 Methylene blue injectable Serotonin toxicity when used in combination with serotonin reuptake inhibitors
Feb 8

Pharmetics Inc.
products

Recall of selected lots of 6 health products
Feb 4

Health products
co-packaged with recalled alcohol prep pads

Recall of Triad alcohol prep pads
Feb 3 Pegetron Redipen Recall of alcohol prep pads co-packaged with Pegetron Redipen
Feb 2 Exact Multi Greens Powder and Capsules

Recall due to allergy risk for people with milk
sensitivities

Jan 28

Nutrex Research
Lipo 6X

Recall of unauthorized weight loss product
Jan 26 Medication It's Your Health: Disposal and use of medication
Jan 25 Medicines It's Your Health: Safe use of medicines
Jan 24 Injectable cosmetic treatments It's Your Health: Injectable cosmetic treatments
Jan 14 Triad products Recall of alcohol swabsticks, swabs and prep pads
Jan 13 Acetaminophen Using acetaminophen safely
Jan 12 Copaxone

Recall of alcohol prep pads co-packaged with
Copaxone

Jan 11 Shandex Sales Group Alcohol Swabs Recall due to potential contamination
Jan 7 Synerate Recall of unauthorized weight loss product
Dec 23 & 24

Probiotic natural
health products

Products may contain trace amounts of milk or soy protein
Dec 15 & 20 Thelin Product withdrawal: concerns about hepatotoxicity
Dec 13 ResurreXX Recall of unauthorized product
Dec 10 "Durazest" and "Once More"

Recall of certain lots of male sex enhancement
products

Dec 10 Rolaid products Recall: reports of foreign materials in products
Dec 10 Flat Stomach Concept Extra Recall because of missing label statements
Dec 7 Semen Information regarding semen donation
Dec 1 "Fat Burner No. 1" Recall of unauthorized product
Nov 25 & Dec 1 Darvon-N Recall and withdrawal: risk of serious abnormal heart rhythms
Nov 24 Children's Benadryl Allergy Meltaways Recall because of quality control concerns
Nov 9 & 18 Avandia, Avandamet and Avandaryl New restrictions because of information on cardiovascular-related events
Nov 13 to Feb 18 Foreign products 20 Foreign Product Alerts (FPAs) were posted on the Health Canada Web site during this period; FPAs are available online or upon request

To receive the Newsletter and health product advisories free by e-mail, subscribe to MedEffect e-Notice.

Canadian Adverse Reaction Newsletter

Health Canada
Marketed Health Products Directorate
Address Locator 0701D
Ottawa ON K1A 0K9
Telephone: 613-954-6522
Fax: 613-952-7738

Editorial Staff
Ann Sztuke-Fournier, BPharm (Editor-in-Chief)
Jared Cousins, BSP
Hoa Ly, BSc
Patricia Carruthers-Czyzewski, BScPhm, MSc
Gilbert Roy, BPharm
Christianne Scott, BPharm, MBA
Sophie Bourbonnais, BScPht

Acknowledgement
We thank the following members of the Expert Advisory Committee on the Vigilance of Health Products for their review of material for this issue: Colleen J. Metge, BSc(Pharm), PhD; Dugald Seely, ND, MSc; and Sylvia Hyland, RPh, BScPhm, MHSc. We also thank Aline Labaki, BSc, LLL, LLB, for her participation in the production of the newsletter.

Suggestions?
Your comments are important to us. Let us know what you think.

Reporting Adverse Reactions
Canada Vigilance Program
Telephone: 1-866-234-2345
Fax: 1-866-678-6789

Copyright
© 2011 Her Majesty the Queen in Right of Canada. This publication may be reproduced without permission provided the source is fully acknowledged. The use of this publication for advertising purposes is prohibited. Health Canada does not assume liability for the accuracy or authenticity of the information submitted in case reports.

Due to time constraints relating to the production of this publication, information published may not reflect the most current information.